Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma

Treatment options in patients with recurrent endometrial carcinoma (EC) are limited and response rates to chemotherapy are poor. Here the authors report the results of a phase II trial of niraparib (PARP inhibitor) monotherapy or in combination with dostarlimab (anti-PD1) in recurrent EC.

Bibliographic Details
Main Authors: Ainhoa Madariaga, Swati Garg, Nairi Tchrakian, Neesha C. Dhani, Waldo Jimenez, Stephen Welch, Helen MacKay, Josee-Lyne Ethier, Lucy Gilbert, Xuan Li, Angela Rodriguez, Lucy Chan, Valerie Bowering, Blaise Clarke, Tong Zhang, Ian King, Gregory Downs, Tracy Stockley, Lisa Wang, Smitha Udagani, Amit M. Oza, Stephanie Lheureux
Format: Article
Language:English
Published: Nature Portfolio 2023-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-37084-w

Internet

https://doi.org/10.1038/s41467-023-37084-w

Similar Items